Anteris Technologies Ltd
ASX:AVR

Watchlist Manager
Anteris Technologies Ltd Logo
Anteris Technologies Ltd
ASX:AVR
Watchlist
Price: 9.3 AUD -3.93% Market Closed
Market Cap: 196.6m AUD
Have any thoughts about
Anteris Technologies Ltd?
Write Note

Anteris Technologies Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Anteris Technologies Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Anteris Technologies Ltd
ASX:AVR
Capital Expenditures
-AU$3.6m
CAGR 3-Years
-131%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Capital Expenditures
-AU$2.5m
CAGR 3-Years
-22%
CAGR 5-Years
-2%
CAGR 10-Years
-18%
Polynovo Ltd
ASX:PNV
Capital Expenditures
-AU$2.9m
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
-43%
SDI Ltd
ASX:SDI
Capital Expenditures
-AU$10.3m
CAGR 3-Years
-36%
CAGR 5-Years
-12%
CAGR 10-Years
-7%
Ansell Ltd
ASX:ANN
Capital Expenditures
-$62.8m
CAGR 3-Years
9%
CAGR 5-Years
-8%
CAGR 10-Years
-2%
Next Science Ltd
ASX:NXS
Capital Expenditures
-$884.5k
CAGR 3-Years
-9%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Anteris Technologies Ltd
Glance View

Market Cap
178.8m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.76 AUD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Anteris Technologies Ltd's Capital Expenditures?
Capital Expenditures
-3.6m AUD

Based on the financial report for Dec 31, 2023, Anteris Technologies Ltd's Capital Expenditures amounts to -3.6m AUD.

What is Anteris Technologies Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-42%

Over the last year, the Capital Expenditures growth was -48%. The average annual Capital Expenditures growth rates for Anteris Technologies Ltd have been -131% over the past three years , -42% over the past five years .

Back to Top